ProCE Banner Activity

Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC

Slideset

Download this slideset from a live symposium at ELCC 2024 for an expert overview of the latest clinical data for TROP-2 ADCs in advanced NSCLC, including monotherapy vs standard-of-care docetaxel in the second-line setting, considerations for biomarker assessment, and future directions with combination regimens and novel TROP-2 ADCs.

Released: March 19, 2024

Expiration: March 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.